Overview

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With Advanced Breast Cancer first-line treatment
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Treatments:
Capecitabine
Docetaxel